I-SPY 2.2 Trial

Design — Phase 2 adaptive neoadjuvant platform (I-SPY 2 TRIAL, since 2010); SMART sequential-randomization Blocks A->B->C with MRI/pre-RCB-guided de-escalation and escalation; MammaPrint/receptor-subtype stratified, high-risk stage 2-3 early breast cancer (NCT01042379). (Nature Medicine 2024)

Primary endpoint — Pathological complete response / low residual cancer burden (RCB), used as an early adaptive readout. (platform design)

First readouts — Datopotamab deruxtecan (Dato-DXd) plus-or-minus durvalumab arms — the first major I-SPY 2.2 results (Nature Medicine 2024; Shatsky et al. for Dato-DXd + durvalumab, Khoury et al. for Dato-DXd alone). (Nature Medicine 2024)

Survival — Overall survival and event-free survival are not yet mature for the I-SPY 2.2 arms; the pCR-to-EFS relationship underpins the platform's design. (platform design)

Platform track record — I-SPY has tested 22 agents since 2010, with 12 completed and 7 graduated in at least one subtype; the 'seamless Phase 2/3' framework was developed with the FDA. (platform design)

Regulatory / Sponsor — INVESTIGATIONAL — I-SPY 2.2 neoadjuvant arms are not FDA approved in this setting. Quantum Leap Healthcare Collaborative with an academic consortium (UCSF, U. Penn, MD Anderson, others; NCI-funded). (FDA / trial design)

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated July 21, 2026.

Pathological Complete Response (pCR) / Low Residual Cancer Burden (RCB) — Primary Early Endpoint (Adaptive Platform, SMART Design)

I-SPY 2.2 is a Phase 2 adaptive platform trial using a Sequential Multiple Assignment Randomized Trial (SMART) design with Blocks A → B → C. Block A: up to 4 novel experimental therapies without standard paclitaxel; patients predicted to have complete response (pre-RCB 0/1 by MRI + biopsy) proceed directly to surgery (de-escalation), while poor-responders proceed to Block B. Block B: subtype-specific best-in-class regimens. Block C: rescue with anthracycline chemotherapy (AC). Biomarker subtypes defined by HR/HER2/MammaPrint (70-gene signature). Specific pCR rates per arm/subtype not fully summarized in available sources; individual arm publications in Nature Medicine 2024 (Dato-DXd ± durvalumab). Prognostic pCR ↔ EFS/DRFS relationship validated from original I-SPY 2.

Overall Survival (OS)

OS/EFS not yet mature for I-SPY 2.2 arms (recent trial evolution). Prognostic relationship between pCR and event-free survival / distant recurrence-free survival is a foundational assumption of the platform design.

Safety & Tolerability

Grade ≥3 TRAE rates are arm-specific and reported in individual Nature Medicine publications (Shatsky et al. for Dato-DXd + durva; Khoury et al. for Dato-DXd alone). Overall safety framework: adaptive de-escalation aims to reduce toxicity by allowing patients with imaging-confirmed complete response to skip further treatment blocks including anthracyclines.

Clinical Implications

🔬 Paradigm-shifting adaptive platform for accelerated neoadjuvant breast cancer drug development. I-SPY 2.2 is the latest evolution of the I-SPY platform (running since 2010; 22 agents tested, 12 completed, 7 graduated in ≥1 subtype). The SMART sequential-randomization design and MRI-based pre-RCB strategy enable BOTH de-escalation (skip AC for predicted CR) AND escalation (add Block B/C for non-responders). Extends original I-SPY 2 with a "seamless Phase 2/3" regulatory framework designed with FDA. Dato-DXd ± durvalumab arms (Nature Medicine 2024) are the first major readouts. Broader implications for accelerated drug development paradigms, validated by adoption in other cancers.

What is the I-SPY 2.2 trial?

I-SPY 2.2 (NCT01042379) is the latest evolution of the I-SPY 2 adaptive neoadjuvant platform trial, which has evaluated novel regimens for high-risk, stage 2-3 early breast cancer since 2010. It stratifies patients by MammaPrint and receptor subtype and uses a Sequential Multiple Assignment Randomized Trial (SMART) design. It is sponsored by Quantum Leap Healthcare Collaborative with an academic consortium.

What is new about the I-SPY 2.2 design?

I-SPY 2.2 introduces a SMART sequential-randomization design with Blocks A, B and C and an MRI-based pre-residual-cancer-burden strategy. This lets the trial both de-escalate therapy (for example, omitting anthracycline chemotherapy for predicted responders) and escalate it (adding subsequent blocks for non-responders), individualizing neoadjuvant treatment within a 'seamless Phase 2/3' framework developed with the FDA.

What were the first I-SPY 2.2 results?

The first major I-SPY 2.2 readouts were the datopotamab deruxtecan (Dato-DXd) arms, with and without durvalumab, published in Nature Medicine in 2024. These reported pathological complete response and residual-cancer-burden outcomes by subtype; overall survival and event-free survival for these arms are not yet mature.

Are the I-SPY 2.2 regimens FDA approved?

No. I-SPY 2.2 is a platform trial that evaluates investigational neoadjuvant regimens, which are not FDA approved in the neoadjuvant early-breast-cancer setting. Some agents are separately FDA approved in other settings (for example, datopotamab deruxtecan is approved for certain metastatic breast cancer), but their use within I-SPY 2.2 is investigational.

Why is I-SPY 2.2 considered important?

I-SPY 2.2 is viewed as a paradigm-shifting platform for accelerating neoadjuvant breast cancer drug development. Its adaptive, biomarker-guided design lets multiple agents be tested efficiently, supports both de-escalation and escalation of therapy, and has influenced adaptive-trial approaches adopted in other cancers.